drugset
Drugs / Aminoglutethimide
last change Dec 2001 re-read 9 days ago

Aminoglutethimide

also known as Aminoglutetimida · Cytadren · NSC-330915 · Orimeten

Small molecule targets CYP11A1, CYP19A1 via inhibition

Developed for
female breast carcinoma · prostate cancer
Investigated by
AstraZeneca · Austrian Breast & Colorectal Cancer Study Group

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) CYTADREN — 1980-10-29 fda.gov ↗

Trials 1

today
US approved 1980
NCT00309491 · Ph 3
1980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT00309491 Dec 1990 → Jan 1996 female breast carcinoma Austrian Breast & Colorectal Cancer Study Group Completed No outcome recorded
Comparator or background therapy1 trial
Phase 2 NCT00006371 Comparator May 2000 → Dec 2001 prostate cancer H. Lee Moffitt Cancer Center and Research Institute Terminated No outcome recorded Stop: Enrollment

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Aminoglutethimide ClinicalTrials.gov intervention name — accepted as the source's own label NCT00309491 ↗
1

NCT00006371 ↗
Known as Aminoglutetimida ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
Known as Cytadren ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
Known as NSC-330915 ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
Known as Orimeten ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
Action Inhibit “Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.” NCT00006371 ↗
2

“Cytochrome P450 19A1 inhibitor” CHEMBL488 ↗

“Cytochrome P450 11A1 inhibitor” CHEMBL488 ↗
Modality Small molecule — CHEMBL488 ↗
Route Oral “Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks.” NCT00006371 ↗
Target CYP11A1 “Cytochrome P450 11A1 inhibitor” CHEMBL488 ↗
Target CYP19A1 “Cytochrome P450 19A1 inhibitor” CHEMBL488 ↗